Drugs / Fiacitabine
Fiacitabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00000981 | ? → Feb 1993 | HIV infectious disease, cytomegalovirus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fiacitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000981 ↗ |
| Known as | FIAC | “To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients” NCT00000981 ↗ |
| Known as | Fiacitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL272557 ↗ |
| Known as | NSC-382097 | ChEMBL registry synonym — accepted as the source's own label CHEMBL272557 ↗ |
| Modality | Small molecule | — CHEMBL272557 ↗ |
| Route | Oral | “FIAC, when taken orally, is readily absorbed into the bloodstream” NCT00000981 ↗ |